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The AGE inhibitor pyridoxamine inhibits lipemia and develop- Advanced glycation end products (AGEs) are post-
ment of vascular and renal disease in Zucker obese rats. translational chemical modifications and cross-links formed
Background. In previous studies, pyridoxamine (PM) lim- in protein by nonenzymatic Maillard reactions of carbo-ited the formation of advanced glycation end products (AGEs)
hydrates with protein. AGEs accumulate in long-livedand development of nephropathy in streptozotocin-diabetic
tissue proteins during normal aging [1], and the acceler-rats without affecting glycemic control. However, the lipid-
lowering effects of PM and the correlation of plasma choles- ated rate of accumulation of AGEs in proteins during
terol and triglycerides with AGEs in skin collagen suggested hyperglycemia is implicated in the development of long-
that lipids might be an important source of AGEs in the dia- term complications of diabetes [1–3]. In a recent study,betic rat. This study addresses the effects of hyperlipidemia on
we reported that the AGE inhibitor pyridoxamine (PM)formation of advanced glycation and lipoxidation end products
[4] significantly inhibited the development of renal dis-(AGE/ALEs) and the effects of PM on hyperlipidemia, hyper-
tension, AGE/ALE formation, and development of nephropa- ease in the streptozotocin (STZ)-induced diabetic rat [5].
thy in the nondiabetic, Zucker obese rat. PM had no effect on glycemic control, but caused a marked
Methods. Three groups of Zucker rats were studied: lean
reduction in albuminuria and plasma creatinine, accom-(Fa/fa), untreated fatty (fa/fa), and fa/fa treated with PM (2 g/L
panied by a decrease in cross linking and formation of thedrinking water). Blood pressure, plasma lipids and creatinine,
and urinary albumin were measured monthly. AGE/ALEs were AGEs, in skin collagen, including Nε-(carboxymethyl)
measured in skin collagen by high-performance liquid chroma- lysine (CML) and Nε-(carboxyethyl) lysine (CEL) and
tography (HPLC) and gas chromatography/mass spectrometry Maillard-type fluorescence, but had no effect on the in-
(GC/MS). Changes in wall thickness of the aorta and renal
crease in the AGE pentosidine,. The STZ-diabetic ratsarterioles were evaluated by light microscopy.
were severely hyperlipidemic and there was an unantici-Results. AGE/ALEs formation was increased two- to three-
fold in skin collagen of obese versus lean rats. PM inhibited pated, more than 50% reduction in triglycerides and
the increases in AGE/ALEs in collagen, and significantly de- total cholesterol in the PM-treated diabetic rat, which
creased the rise in plasma triglycerides, cholesterol, and creati- correlated significantly with the improvement in renalnine, corrected hypertension and thickening of the vascular
function and the decrease in AGEs. In other studies, wewall, and nearly normalized urinary protein and albumin excre-
had observed that PM was not only an AGE inhibitor,tion in Zucker fa/fa rats.
Conclusion. Lipids are an important source of chemical but also a potent inhibitor of formation of advanced
modification of tissue proteins, even in the absence of hypergly- lipoxidation end products (ALEs) during lipid peroxida-
cemia. PM inhibited AGE/ALE formation and hyperlipidemia tion reactions in vitro [6]. Because CML and CEL mayand protected against renal and vascular pathology in a nondia-
be formed from lipids [7] (i.e., they are both AGEsbetic model.
and ALEs), and because hyperglycemia and pentosidine
formation were unaffected by PM, we considered that
CML and CEL, fluorescence and cross linking of colla-
gen in the STZ-diabetic rat might result primarily from
lipoxidation rather than glycoxidation reactions and that
Key words: Advanced glycation end product (AGE), advanced lipoxi-
PM might be working primarily as a ALE inhibitor indation end-product (ALE), dyslipidemia, hyperlipidemia, hyperten-
sion, nephropathy, pyridoxamine, Zucker rat. the diabetic rat.
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hyperlipidemia, in the absence of hyperglycemia, causesand in revised form December 5, 2002
Accepted for publication February 3, 2003 an increase in levels of AGEs (pentosidine), ALEs [ma-
londialdehyde-lysine and hydroxynonenal-lysine (MDA- 2003 by the International Society of Nephrology
2123
Alderson et al: Pyridoxamine treatment of Zucker obese rats2124
Lys, HNE-Lys)] and common products of carbohydrate water. The dose of PM was chosen to be consistent with
the dose used in a previous study in nondiabetic Sprague-and lipid autoxidation, CML and CEL, which are termed
AGE/ALEs. If so, we proposed to determine whether Dawley rats [5], and was well tolerated by both the
Sprague-Dawley and Zucker rats. Mean intake of PMPM also inhibited AGE/ALE formation and develop-
ment of renal disease in a hyperlipidemic, nondiabetic in FPM rats was 60  5 mg/kg/day.
animal model of nephropathy. The Zucker fa/fa rat was
Plasma and blood analyseschosen for these studies because of its chronic hyperlipid-
emia, resulting from a homozygous defect in the leptin Blood was obtained from the tail vein using heparin-
ized microhematocrit tubes, and plasma recovered byreceptor, the absence of hyperglycemia, and its suscepti-
bility to development of chronic renal disease [8, 9]. This centrifugation at 4C. Plasma concentrations of glucose,
triglycerides, total cholesterol, creatinine, and red cellrat model has many of the features of human syndrome
X [10, 11], since these animals are not only hyperlipid- total glycated hemoglobin were all analyzed using com-
mercial kits as described previously [5]. Control experi-emic and obese, but also hypertensive and insulin-resis-
tant [12]. The Zucker diabetic fatty (ZDF) rat, a sub- ments showed that PM, at concentrations present in
plasma, did not cause interference in any of the assays.strain of these animals, is susceptible to diet-induced,
type 2 diabetes [13]. Insulin was measured using a sandwich enzyme-linked
immunosorbent assay (ELISA) for rat insulin (ALPCO,In this study, we show that the formation of the AGE/
ALEs, CML, and CEL, as well as the AGE pentosidine, Windham, NH, USA). Plasma and urinary PM concen-
trations were measured by reverse-phase high-perfor-and the ALEs, MDA-Lys, HNE-Lys, is significantly in-
creased in skin collagen of the hyperlipidemic, normogly- mance liquid chromatography (RP-HPLC) with fluores-
cence detection, using 293/393 nm excitation and emissioncemic Zucker fa/fa rat. We also show that PM signifi-
cantly inhibits the chemical modification of proteins by wavelengths [14].
AGE/ALEs, the development of hyperlipidemia, and
Nephropathythe progression of renal and vascular pathology and hy-
pertension in this animal model. Our results point to a Progression of renal disease was assessed by measure-
ments of plasma creatinine and 24-hour urinary albuminsignificant role for lipids in the chemical modification of
proteins in diabetes and illustrate the possible merits of and total urinary protein, as described previously [5].
For urine collections, rats were housed in metabolic ratPM therapy for inhibiting AGE/ALE formation, hyper-
lipidemia, and vascular and renal disease in diabetes and cages for 24 hours with free access to food and water.
Several drops of toluene were added to the urine collec-morbid obesity.
tion beaker to inhibit microbial growth. Urinary albumin
was quantified by an ELISA assay [5]. Total urinary
METHODS
protein was measured using the Sigma Microprotein-PR
Materials Kit (Sigma Chemical Co.). In experiments in which known
amounts of PM were added to urine, PM increased thePM(HCl)2 (Pyridorin) was provided by Biostratum,
Inc. (Research Triangle Park, NC, USA). Except as indi- final absorbance readings in the protein assay, so that a
correction (10%) was applied for the PM content ofcated, all other biochemicals were from Sigma Chemical
Co. (St. Louis, MO, USA). Phosphate-buffered saline the urine.
(PBS) solutions contained 1 mmol/L diethylenetriamine-
Blood pressurepentaacetic acid (DTPA) to inhibit metal-catalyzed oxi-
dation chemistry during sample preparation and storage. Blood pressure measurements were made by tail-cuff
plethysmography using a Kent Scientific (Torrington,
Animals and treatments CT, USA) XBP instrument. The measurements were
initiated at week 5 in the experiment after acclimatingAll experiments were carried out with approval of, and
in accordance with the regulations of, the Institutional the animals to the apparatus.
Animal Care and Use Committee of the University of
Necropsy and tissue samplingSouth Carolina. Female Zucker obese (fa/fa) rats (N 
14) and lean (LN) littermates (Fa/fa) (N  7) were pur- Blood was collected into heparinized vacutainer tubes
from anaesthetized (isoflurane) rats by heart puncture,chased at 6 weeks of age from Charles River Labora-
tories (Wilmington, MA, USA), and were housed indi- then stored on ice. Plasma was separated from whole
blood within 30 minutes by centrifugation in a refriger-vidually with a light-dark cycle of 12 hours each, and
with free access to food and water. The fa/fa rats were ated bench-top centrifuge; aliquots of plasma were
stored at 70C until time of analysis. Rats were thendivided randomly into two groups of seven each, un-
treated fatty control (FC) and PM-treated (FPM) ani- killed by overanesthetization, the renal and hepatic ar-
teries were clamped, and the heart and aorta fixed bymals, the latter group receiving 2 g PM/L in the drinking
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Table 1. Glycemic control and glycation of protein in variousinjection of buffered neutral formalin into the left ventri-
groups of ratsa
cle. Liver and kidneys were then removed, both organs
Week 0 Week 16 Week 32rinsed in PBS, and weighed. One kidney was cut in half
Plasma glucoseb mmol/Ltransversely, and one half was removed for formalin
LN 6.70.5 6.60.5 6.60.4fixation for light microscopy. The remaining kidney and FC 7.20.7 7.10.4 6.90.2
FPM 6.80.5 6.90.6 6.80.5liver samples were frozen at70C. A section of abdomi-
Glycated hemoglobinb %nal skin (2 cm2) was also removed, rinsed in PBS and
LN 6.40.5 6.30.6 6.70.3stored at 70C.
FC 6.70.2 6.60.3 6.80.2
FPM 6.80.5 6.50.3 6.80.3
Morphologic techniques Glycation of skin collagenc FL mmol/mol lysine
Week 0 Week 11 Week 32Tissue for light microscopy was fixed in neutral buf-
LN 3.60.2 4.00.1 4.50.3fered 10% formalin, embedded in paraffin, and pro-
FC 3.50.2 3.00.1d 2.30.2e
cessed by routine histologic procedures. Hematoxylin FPM 3.50.2 3.00.1d 2.30.3e
and eosin–stained 5 m thick sections from heart, aorta, Abbreviations are: LN, lean; FC, untreated fatty controls; FPM, pyridoxamine
(PM)-treated; FL, fructose lysine.and kidney were examined in a blinded manner by light
a Data are meansSD for seven animals per group
microscopy. b Plasma glucose and % total glycated hemoglobin are representative of data
at all time points during the study
c Skin biopsies were taken at week 0, 11 and 32. Glycation (FL) measured in
Morphometry insoluble collagen by selected ion monitoring-gap chromatography/mass spec-
tometry (SIM-GC/MS) as described in the Methods section
The thickness of each artery wall was measured with d P  0.01 vs. LN rats, and vs. rats in same group at week 0
e P  0.01 vs. LN rats, and vs. rats in same group at week 11an eyepiece micrometer at 420 magnification at the
limit between adventitia and the surrounding connective
tissue and the intima. The axis measurement (a) between
two opposite adventitial points was considered as the differences in mean age of the protein [18, 19] (see Table 1
diameter of the artery. The measurement (b) between and Discussion, below). Collagen fluorescence (Ex 
the opposite intimal points was considered the luminal 370 nm, Em 440 nm) was measured after solubilization
diameter. The thickness of the artery wall (w) was calcu- with pepsin (20 ug/mL in 0.5 mol/L acetic, 24 hours at
lated from the formula w  (a  b)/2 and was expressed 37C), and was normalized to the hydroxyproline content
as the percentage of artery diameter. of the collagen, measured as described by Stegemann
The surface area of renal corpuscles was measured as and Stalder [20].
described by Bauer and Rosenberg [15]. Seven nonscle-
Statistical analysisrotic corpuscles were measured in each animal. Long
All samples were analyzed in a blinded manner. Statisti-and short axis measurements were used to calculate the
cal analyses were performed using SigmaStat for Windowsarea (pab/4) of all renal corpuscles encountered on a ser-
V1.00 (SPSS, Inc., Chicago, IL, USA) or Instat (Graphpad,pentine course between cortex and medulla. Measure-
San Diego, CA, USA). P values were calculated by non-ments of the longest axis (a) and the shortest axis (b) were
parametric Mann-Whitney rank sum analysis. Correla-made with an eyepiece micrometer at420 magnification
tion analyses were performed by the Pearson productbetween the parietal layer of the Bowman’s capsule.
moment method. Differences in arterial wall thickness
were analyzed by analysis of variance (ANOVA) withAssays of chemical modifications and fluorescence in
Bonferroni multiple comparisons test.skin collagen
The insoluble fraction of skin collagen was prepared
RESULTSby scraping the skin with a single-edged razor blade to
remove hair and adventitious tissue, followed by extrac- Weight gain and glycemic control
tions with 0.5 mol/L NaCl, 0.5 mol/L acetic acid and chlo- Zucker fa/fa rats weighed significantly more than LN
roform/methanol (2:1 vol/vol), as described previously littermates at week 0 of the study (6 weeks of age; LN 
[16]. Fructoselysine (FL), a measure of glycation of colla- 158.5  10.8 g and fa/fa  237  14.3 g, respectively).
gen, and CML, CEL, MDA-Lys and HNE-Lys were FC and FPM rats weighed 2.5-times more than LN
assayed by isotope dilution, selected ion monitoring-gas rats at 32 weeks: LN  267  26 g; FC  721  81g; and
chromatography/mass spectrometry (SIM-GC/MS), and FPM 746 60 g). There was no statistically significant
pentosidine by RP-HPLC, all as described previously difference in body weight between FC and FPM rats at
[16, 17]. Levels of AGEs/ALEs were expressed relative any point in the study. Plasma concentrations of PM,
measured at 32 weeks into the study, were increasedto the FL content of the collagen in order to correct for
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sixfold in FPM, compared to LN and FC animals (LN
0.44  0.08 mol/L; FC  0.38  0.05 mol/L; FPM 
2.7  3.0 mol/L).
In agreement with previous studies [5], PM had no
effect on glycemia. Despite the large differences in body
weights between the LN versus FC and FPM groups,
mean fasting blood glucose was 6.5 mmol/L and mean
total glycated hemoglobin 6.8% in all three groups
throughout the 32-week experiment (Table 1). However,
there were significant differences in collagen glycation
between the LN and fatty groups, with FL levels increas-
ing by 25% in the LN group with age, but declining
about 35% in FC rats (Table 1). FL increases modestly
in human skin collagen with age, and is thought to reflect
an age-dependent decrease in glucose tolerance. At the
same time, the fatty rats are growing at a substantially
greater rate than the LN animals, so that their total skin
surface area and collagen mass are growing constantly,
especially at early stages of the study. Thus, the lower
mean age of skin collagen in the FC and FPM rats re-
sulted in lower FL concentrations in collagen of these
animals. Consistent with the similar growth rate and
weights in the two fatty groups, FL in skin collagen was
the same for both groups, further demonstrating that
Fig. 1. Pyridoxamine inhibits dyslipidemia in Zucker fa/fa rats. FastingPM had no effect on glycemic control (Table 1).
plasma triglycerides (A) and total cholesterol (B) were measured usingFasting plasma insulin levels were 0.6  0.1 g/L in commercial kits, as described in the Methods section. Means  SD are
LN rats, measured at 0 weeks, and remained unchanged shown for each group: Lean (LN) (), untreated fatty control FC ()
and pyridixamine (PM)-treated (FPM) (). At the end of the study,at 16 and 32 weeks. Plasma insulin levels were signifi-
each of the three groups were significantly different from one anothercantly higher in fa/fa rats at the beginning of the study (P  0.0001 between groups for triglycerides. For cholesterol, FPM vs.
(5.6  0.3 g/L) and rose to 7.1  0.6 g/L and 7.3  LN, P  0.05; FC vs. FPM, P  0.0001.
0.6 g/L in FC and FPM rats, respectively, at 32 weeks,
without a significant change in blood glucose concentra-
tion. Thus, PM did not significantly affect the develop-
toward decreasing cholesterol in FPM rats after weekment of hyperinsulinemia or insulin resistance in fa/fa
16. Overall, PM significantly reduced dyslipidemia, bothanimals, nor, as shown below, were hyperinsulinemia
triglycerides and cholesterol, in the fa/fa rat, without af-and insulin resistance alone sufficient to induce renal
fecting overall weight gain, glycemia or insulin resistance.dysfunction and hypertension in the Zucker rat.
Renal function and histologyDyslipidemia
Urinary volumes were 27.3  7.1 mL/24 hours, 31.6 There were significant increases in fasting plasma tri-
6.3 mL/24 hours, and 26.0  5.5 mL/24 hours, respec-glycerides and total cholesterol in FC, compared to LN
tively, in LN, FC, and FPM groups at week 32 of therats (Fig. 1). Triglycerides in the LN group rose slightly
study (P 	 0.05 between groups). Total urinary proteinduring the first 2 months of the study, but remained at
and albumin and plasma creatinine were measured to100 mg/dL thereafter. In contrast, in FC rats triglycer-
evaluate the effect of PM on renal function. Already byides rose continuously throughout the study, reaching a
week 6 of the study, both total urinary protein and albu-mean value of 800 mg/dL at 32 weeks. There was an
min were rising in the FC compared to LN and FPMearly increase in triglycerides in the FPM group, which
animals (Fig. 2 A and B). Urinary albumin increased towas markedly blunted after 10 weeks. Thereafter, triglyc-
10-fold above basal levels in FC versus LN rats at 32erides remained in a relatively narrow range in the FPM
weeks, and was paralleled by similar increases in totalgroup, 50% of the values seen in FC animals. Plasma
urinary protein. PM provided nearly complete protectioncholesterol rose slightly in the LN group during the ex-
against development of proteinuria, as well as the in-periment, but was generally in the range of100 mg/dL.
crease in plasma creatinine concentration in the fa/faCholesterol rose to approximately 250 mg/dL in FC rats,
rats (Fig. 2C).but to only 150 mg/dL in FPM rats, 50% higher than
in LN animals. As with triglycerides, there was a trend Since a significant increase in the glomerular volume
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Fig. 3. Pyridoxamine (PM) prevents the increase in systolic blood pres-
sure in the Zucker fa/fa rats. Animals were acclimated for blood pres-
sure measurements during the first month of the study, then tested at
4- to 6-week intervals. Blood pressures of lean (LN) () and PM-
treated (FPM) () groups were not significantly different from each
other throughout the study, while blood pressure of the untreated fatty
control (FC) () group rose gradually during the course of the study.
Means  SD are shown for each group. At the end of the study, FC
vs. other groups, P  0.001; LN vs. FPM, not significant.
significantly different from one another (mean  SE 
LN, 1395  56 m2; FC, 2053  74 m2; FP, 1929  58
m2). About 15% of glomeruli in FC rats showed
changes consistent with focal glomerulosclerosis, with
increased mesangial cellularity and adhesion between
the tuft and Bowman’s capsule. These glomerular changes
were rare in LN rats, and appeared less common in FPM
versus FC rats, but were not evaluated quantitatively
because of their infrequent occurrence.
Blood pressure and vascular changes
Animals in all groups had mean systolic blood pressure
in the range of 125 to 130 mm Hg at week 5 of the study.
Systolic blood pressure rose gradually in the FC rats to
Fig. 2. Pyridoxamine (PM) protects against renal disease in Zucker 165 mm Hg, while it remained at initial values for LN
fa/fa rats. Animals [lean (LN) (), untreated fatty control (FC) () and FPM groups, with no statistical differences betweenand PM-treated (FPM) ()] were housed in metabolic cages and 24-
LN and FPM groups throughout the study (Fig. 3).hour urine collected for analysis of total urinary protein (A) and albumin
(B); creatinine (C) was measured in fasting plasma. Urinary albumin and Longitudinal sections of the aorta from LN, FC, and
plasma creatinine were measured using commercial kits, and albumin FPM rats were examined from the aortic root to theby enzyme-linked immunosorbent assay (ELISA), as described in the
bifurcation. The photomicrographs in Figure 4 A to CMethods section. Means  SE are shown for each group. At the end
of the study, FPM vs. LN was significant. P  0.05 for urinary protein illustrate the vascular changes that occurred in the aorta
and albumin, and P  0.01 for plasma creatinine. FC was significant of FC rats, compared to LN littermates. Thickening offrom LN and FPM, P  0.0001.
the media layer and the presence of intracellular, possi-
bly lipid, vacuoles were consistently observed in the aorta
of FC rats, but not in LN or FPM rats. In LN rats there
were six to eight cell layers delimited by elastic lamellae,has been described in obese Zucker rats [21], we exam-
ined whether this morphologic parameter was modified whereas there were four to six additional layers, with
some layer disorganization, in the aorta of FC rats. Thein FPM compared to FC rats. FC rats had a significant
increase in the renal corpuscle area compared to LN cell number was also increased, in concert with thickening,
in the aortic wall in FC rats, consistent with a proliferativerats (P  0.01); however, FPM and FC rats were not
Alderson et al: Pyridoxamine treatment of Zucker obese rats2128
Fig. 4. Pyridoxamine (PM) protects against structural changes in the aortic and coronary vasculature in Zucker fa/fa rats. Characteristic sections of
aortas from lean (LN) (A), untreated fatty control (FC) (B) and PM-treated (FPM) (C) rats, and of coronary arteries from FC (D) and FPM (E) rats.
response by medial smooth muscle cells. All of these metric analysis of small heart arteries (100 m diame-
ter) showed a significant increase in the thickness in FCchanges were nearly normalized in FPM rats (Fig. 4C).
There was no evidence of atherosclerotic plaque or ath- compared to LN and FPM rats (Fig. 4 D and E). Small
artery wall thickness was significantly increased in FCerogenesis in the aorta of any of the Zucker rats.
Sections of the coronary and renal vasculature were compared to LN rats, and the increase was 90% inhib-
ited in the FPM rats (Fig. 5A). A similar increase inexamined in greater detail by light microscopy. Morpho-
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Fig. 5. Pyridoxamine (PM) inhibits thickening of walls of cardiac and
renal arterioles in Zucker fa/fa rats. (A ) Cardiac small artery thickness
(mean  SD). Lean (LN) (), 19.2%  5.7%; untreated fatty control
(FC) ( ), 27.9%  6.9%; and PM-treated (FPM) (), 15.8%  5.7%.
LN and FPM, P  0.001 vs. FC. LN vs. FPM, P 	 0.05. (B ) Renal
small artery thickness. LN, 16.9%  5.4%; FC, 29.8%  8.8%; FPM,
26.0%  4.3%. LN vs. FC and FPM, P  0.001; FC vs. FPM, P  0.05.
Fig. 6. Pyridoxamine (PM) inhibits the increase in AGE/ALEs in skin
collagen of Zucker fa/fa rats. Skin biopsies were obtained at the indi-wall thickness was noticeable in small branches of the
cated times and insoluble collagen prepared as described in the Methodscoronary arteries of the myocardium (data not shown). section. Nε-(carboxymethyl) lysine (CML) (A) and Nε-(carboxyethyl)
The average wall thickness of small arteries in FC rat lysine CEL (B) were quantified by selected ion monitoring-gas chroma-
tography/mass spectrometry (SIM-GC/MS) and pentosidine (C) by re-kidney was also significantly greater than that of LN rats
verse-phase high-performance liquid chromatography (RP-HPLC).and showed a bimodal distribution (Fig. 5B). PM caused Data are shown as means  SD for lean (LN) (), untreated fatty
a partial reversion of thickness toward that of LN ani- control (FC) () and PM-treated (FPM) () groups. At the end of the
study, for CML and CEL, FC vs. LN or FPM, P 0.001. For pentosidine,mals, having a greater effect on the frequency of arteries
FPM vs. FC, P  0.07; FPM vs. LN, P  0.05.with thicker walls. Although PM did not completely pre-
vent the thickening of renal artery walls in fa/fa rats, the
cardiac and renal vascular changes observed in FC rats
Chemical modifications in skin collagenwere consistent with a response to hypertension, and
As shown in Figure 6, the AGE/ALEs, CML and CEL,both the hypertension (Fig. 3) and vascular changes (Fig.
and the AGE pentosidine, increased modestly with age4) were, to a significant extent, normalized in the FPM
rats. in LN animals, but at a significantly greater rate in the
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Table 2. Levels of advanced lipoxidation end products (ALEs) and fluorescence in skin collagen of lean (LN), untreated fatty controls
(FC), and pyridoxamine (PM)-treated (FPM) rats
Week 16 Week 32 Week 32 Week 32
Analyte MDA-Lysa (mmol/mol Lys) MDA-Lys (mmol/mol Lys) HNE-Lysa (mmol/mol Lys) Fluorescenceb Units/mol FL
LN NDc ND ND 0.050.02
FC 0.570.1 (3/7)d 0.680.3 (7/7) 0.0110.005 (7/7) 0.100.03e
FPM ND Trace (3/7)d ND 0.050.02
a Malondialdehyde Schiff base adduct tolysine residues in protein (MDA-Lys) and hydroxynonenal Michael adduct to lysine residues in protein (HNE-Lys) were
analyzed in skin collagen of all animals in each group by selected ion monitoring-gas chromatography/mass spectrometry (SIM-GC/MS). Numbers in parentheses
indicate number of samples in which MDA-Lys or HNE-Lys was measurable.
b Fluorescence was measured only in necropsy samples
c Not detectable
d MDA-Lys was detectable in only three of seven FC animals at 16 weeks; mean of these three measurements is shown. MDA-Lys was detected in three of seven
FPM animals at week 32, but could not be reliably quantified.
e P  0.05 vs. LN and FPM groups
FC animals. Notably the increase in these compounds, fications of proteins. It is now recognized that some com-
including pentosidine, which is derived exclusively from pounds, such as CML and CEL, and probably the imida-
carbohydrates [7], were comparable in magnitude to zolium cross-links, GOLD and MOLD [22], may be
changes observed previously in STZ-diabetic rats [5], derived from either carbohydrates or lipids, leading to their
but occurred in the FC animals in the absence of hyper- designation as AGE/ALEs. Other compounds appear to be
glycemia. PM treatment inhibited the increase in CML true AGEs (e.g., pyrraline, glucosepane, 3-deoxyglucosone
and CEL in skin collagen in fa/fa rats, and was also imidazolone), adducts to arginine, and the fluorescent cross-
effective in limiting the increase in pentosidine through links, pentosidine, cross lines and vesperlysines. MDA-
week 11 of the study, but by week 32 the differences in Lys, HNE-Lys, and larger levuglandin and phospholipid
pentosidine between FC and FPM rats was only margin- adducts to proteins are ALEs, derived exclusively from
ally significant. MDA-Lys and HNE-Lys represent chemi- lipids [23].
cal modifications that are uniquely derived from lipid One of the novel observations of the present work is
peroxidation products, so that they can be clearly classi- that levels of the entire group of compounds, including
fied as ALEs. Neither of these ALEs was detectable in AGEs (pentosidine), ALEs (MDA-Lys and HNE-Lys),
skin collagen from LN animals at any time point. By 11 and AGE/ALEs (CML and CEL), as well as Maillard-
weeks, three of seven FC rats had measurable quantities type fluorescence, are increased significantly in skin col-
of MDA-Lys in their skin collagen, and by 32 weeks lagen of the Zucker obese, hyperlipidemic fa/fa rat, even
this ALE was measurable in collagen of all FC animals in the absence of diabetes (hyperglycemia) or atheroscle-
(Table 2). In contrast no MDA-Lys was detectable in rosis. Except for pentosidine, the increase in these com-
the FPM rats until 8 months, and then only in trace pounds can be attributed entirely to the hyperlipidemia.
amounts, 2 mol/mol FL in three of seven animals. The elevation of pentosidine in a normoglycemic animal
HNE-Lys was not measurable in any skin sample from is difficult to explain, suggesting that pentosidine may
LN animals; it was found in FC animals at 8 months, but be derived from ascorbate or a precursor other than
was not detectable in the FPM group. Because of the glucose. In addition to AGEs and AGE/ALEs, we have
limited sample available, collagen fluorescence was mea- detected, for the first time, MDA and HNE adducts to
sured only in necropsy samples. As shown in Table 2, lysine residues in rat skin collagen. The fold increase
Maillard-type fluorescence was twofold higher in the FC cannot be estimated because of the low levels ( 2mol/
compared to LN animals, and PM treatment prevented mol FL) of these compounds in the LN rats, but, as
this increase. observed in previous studies, the concentration of MDA-
Lys was significantly greater than that of HNE-Lys [17].
These ALEs are probably steady-state indicators of the
DISCUSSION
degree of lipemia, since both adducts retain a reactive
Increased chemical modification of proteins in the functional group and could continue to react with nucleo-
Zucker fa/fa rat philic groups in protein to form cross-links [17] and pyr-
role [24] derivatives. Regardless of the source or mecha-For nearly 20 years, the increase in AGEs in tissue
nism of formation of various products in protein, lipidsproteins in diabetes has been ascribed to the increase in
appear to be important sources of chemical modificationsglycemia. However, in 1996 Fu et al [7] demonstrated that
and cross-links in proteins, including CML, the majorthe AGEs, CML and CEL, were also formed on proteins
AGE formed during nonenzymatic glycoxidation of pro-during lipid peroxidation, introducing confusion into
both the origin and nomenclature of nonenzymatic modi- teins. There is increasing recognition of the role of blood
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lipids as risk factors for development of renal and vascu- as a primary cause of vascular and renal disease in fa/fa
rats, and the effects of PM could be attributed directlylar disease in diabetes [25, 26] and obesity [27, 28], sug-
gesting that lipids may be as important as carbohydrates to the trapping of reactive carbonyl or dicarbonyl precur-
sors of AGE/ALEs. In recent work, we have detectedin the pathogenesis of chronic disease.
several PM derivatives in the urine of PM-treated dia-
Effect of PM on chemical modification of proteins in betic and fa/fa rats, which are also formed during lipid
the Zucker rat peroxidation and lipoxidation reactions in vitro [6]. The
detection of these urinary products, including the hexa-PM was first described by Booth et al [29, 30] as a post-
Amadori inhibitor of AGE formation. PM is a potent noic amide derivative of PM, an analog of Nε-hexanoyl-
lysine identified in atherosclerotic plaque by Kato et alnucleophile and may trap dicarbonyl intermediates in
AGE formation [31]. Onorato et al [6] demonstrated [33], indicates that PM functions, at least in part, to trap
intermediates in AGE/ALE formation in vivo.that PM also inhibited ALE formation from peroxidizing
lipids and lipoproteins in vitro, and identified hexanoic Although the AGE/ALE inhibitory activity of PM
provides a tenable explanation for the therapeutic effectsand nonanedioic acid monoamide adducts to PM as ma-
jor products formed during inhibition of formation of of PM, we cannot rule out the alternative hypotheses
that the beneficial effects of PM are secondary to itsCML, CEL, MDA-Lys, and HNE-Lys from peroxidizing
lipids. The broad-spectrum inhibition of formation of lipid-lowering activity. In this context, both dyslipidemia
and hyperlipidemia are recognized as independent riskthese same compounds in collagen of fa/fa rats is consis-
tent with the action of PM in vitro. In general, the frac- factors for development of renal disease [34, 35]. Glo-
merular infiltration by macrophages precedes albumin-tional inhibition of formation of AGE/ALEs (CML,
CEL) and ALEs (MDA-Lys, HNE-Lys) is greater than uria and morphologic changes in the kidney of Zucker
rats [36], possibly the result of a lipid-induced inflamma-the fractional decrease in lipidemia, arguing that inhibi-
tion of AGE/ALE formation by PM is not attributable tory process. Reduction of plasma lipids by treatment with
hydroxymethylglutaryl-coenzyme A reductase inhibitorsentirely to the reduction in plasma lipid concentration.
The inhibition of pentosidine formation in the present (mevinolin [37] and lovastatin [38]), clofibric acid [36]
or acarbose [39], also provides protection against ne-studies (Fig. 5) is not as impressive, but is consistent with
previous studies in the STZ-diabetic rat [5] and other phropathy in the fa/fa rat. Our studies are consistent with
a role for hyperlipidemia in the development of renalwork (personal communication, Voziyan, P.A., Depart-
ment of Medicine, Vanderbilt University) indicating that disease because the increase in lipemia precedes the de-
velopment of nephropathy. However, the fractional de-PM is less efficient in inhibiting the formation of pentosi-
dine from glycated proteins in vitro. crease in AGE/ALEs and protection of renal and vas-
cular disease by PM was significantly greater than the
Mechanism of PM protection against renal and fractional decrease in plasma lipids. Although threshold
vascular disease effects cannot be excluded, these observations suggest
that there is an added beneficial effect, beyond the lipid-PM had profound effects on hyperlipidemia, chemical
modification of proteins, hypertension, and progression lowering effects of PM. Thus, assuming that hyperlipid-
emia causes renal injury via inflammation and associatedof renal and vascular disease in the fa/fa rat. Which is
the primary target of PM action? From the perspective lipid peroxidation reactions, PM may protect the kidney
by both its lipid-lowering effects and by protectionof the Maillard hypothesis, diabetic complications are a
consequence of increased formation of AGEs during against lipoxidative damage. Direct antioxidant effects
are unlikely because PM is only a weak chelator [40]hyperglycemia. By expanding this hypothesis to include
pathology resulting from formation of ALEs during hy- and does not inhibit lipid or lipoprotein oxidation, even
at 100 umol/L concentrations in vitro [5].perlipidemia, all of the beneficial effects of PM in the
fa/fa rat could be attributed to PM’s activity as an inhibi- A third hypothesis posits that renal failure is the pri-
mary pathology in the Zucker rat. Because uremia causestor of AGE/ALE formation. Thus, by inhibiting the
chemical modification and cross-linking of renal and vas- an increase in CML, CEL, and pentosidine in plasma
and tissue proteins, independent of diabetes or hyperlip-cular collagens, PM may reduce the thickening and loss
of elasticity of the vascular wall, preserving renal and idemia [41], renal failure may cause the increase in AGE/
ALEs in tissues of fa/fa rats. Hyperlipidemia is also asso-vascular function and preventing the development of
dyslipidemia and hypertension. The reduction in AGE/ ciated with nephrotic syndromes, independent of diabe-
tes [42, 43], and protection of renal function by PM mayALE formation by PM might also limit inflammatory
processes resulting from increased oxidant production therefore inhibit hyperlipidemia. The decrease in lipid
precursors of AGE/ALEs and ALEs could limit theon interaction of AGE/ALEs with the receptor for AGE
(RAGE) [32]. In this context, the chemical modification chemical modification of tissue proteins, independent of
a direct inhibitory effect of PM on AGE/ALE formation.of proteins by lipoxidation reactions would be viewed
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